Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theragnostics Ltd.
Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.
A Reprint--see the article of the same name in In Vivo, May 2008.
In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
- Other Names / Subsidiaries
- Theragnostics, Inc.